Vasilis has worked at and consulted for several pharmaceutical and biotech companies globally. Due to his innovation he has been the founder and director of four biotech companies since 2000, was involved in raising over 30 million dollars in capital for these companies, sold biotech products that have achieved over 100 million dollars in sales, and has sold intellectual property involved in two successful IPO’s on the ASX. After finishing his doctorate in pharmacology in 1993 at St Vincent’s Institute of Medical Research at the University of Melbourne, he completed his post-doctoral fellowship at Pfizer Central Research in Connecticut. During this time he was awarded two scholarships from the Australian Dairy Research and Development Organisation, and the National Health and Medical research Council of Australia and two young investigators awards in osteoporosis research from the Australian and New Zealand Bone and Mineral Society, and the International Society for Bone and Mineral Research. After doing his clinical training in Greece, he worked in combat trauma medicine in Africa where he stayed and did humanitarian work in Angola. In 2008, Dr. Paspaliaris received an Appreciation Award from the American Association of Clinical Endocrinologists for his ground-breaking work on adipose-derived stem cells and two certificates of appreciation from the American Academy of Anti-Aging Medicine on his stem cell research and an investigators award from the Hellenic Thoracic Society in what was the first published formal human clinical trial on the effect of mesenchyme stem cells on idiopathic lung fibrosis. Dr. Paspaliaris has published over 25 papers, holds over 7 patents and given lectures in a variety of medical fields, mostly in pharmacology and regenerative medicine. He was a Faculty Member for the Master degree program in Clinical Pharmacology and Therapeutics at Democritus University Medical School in Greece from 2011-2017. He is currently a member of the American Society of Clinical Pharmacology and Therapeutics and a Fellow of the Royal Society of Medicine (UK). More recently he has completed postgraduate certificates in Genetic CRISPR Engineering from Harvard University, and two postgraduate certificates in Artificial Intelligence, one from MIT and one form Oxford University. He is the founder and director of Paspa Pharmaceuticals Pty Ltd incorporated in 1996, founder and President of Tithon Biotech Inc incorporated in 2014, and recently the founder and director of Poseidon Biolabs Pty Ltd.